Skip to navigation Skip to content

Clinical Trial: Impact of Vancomycin on the Gut Microbiome and Immune Function in MS

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To affect gut microbiome
Number of Subjects: 40
Medication: Vancomycin
Location: Connecticut|New Jersey|New York
Institutions: Icahn School of Medicine at Mount Sinai
5 East 98th Street, New York, NY 10029 Contact Information
Susan Filomena
212-241-6604
susan.filomena@mssm.edu

Funding:

The Doris Duke Foundation

Description

The goal of this study is to see if changes in the gut microbiome can alter multiple sclerosis outcomes. Participants are newly diagnosed with MS (symptoms onset lest than 6 months) who have never taken disease-modifying treatment. Participants will take vancomycin, an antibiotic, four times daily for 30 days before beginning the MS treatment of their choice. They will complete several MRIs and provide blood and stool samples. Participation is expected to last a little more than one year. Partiipants will be compensated for their time and procedures.
 

Share


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.